Questions: Antipsychotics: Mechanisms and Clinical Application

Question 1

A patient with schizophrenia has been on an atypical antipsychotic for six months. Their hallucinations have nearly resolved, but they show persistent flat affect, social withdrawal, and difficulty initiating tasks. What does this clinical picture illustrate?

• A. Medication failure — a well-dosed antipsychotic should eliminate all symptoms
• B. Tardive dyskinesia — the motor symptoms are masking the patient's emotional expression
• C. The typical treatment gap: antipsychotics are highly effective for positive symptoms but do little for negative symptoms, which often determine long-term functional outcome
• D. Metabolic syndrome presenting as psychiatric symptoms

Answer: (C)

This is the core clinical limitation of antipsychotics. Positive symptoms (hallucinations, delusions, disorganized thinking) respond well to D2 blockade. Negative symptoms (flat affect, alogia, avolition, social withdrawal) are largely unresponsive — and these are often the bigger determinants of whether a patient can hold a job, maintain relationships, or live independently. Second-generation antipsychotics modestly improve negative symptoms in some patients via serotonergic modulation, but the effect is limited. Option B describes a motor side effect, not a presentation of negative symptoms. Understanding this distinction is essential for realistic treatment planning.

Question 2

Why do first-generation (typical) antipsychotics cause extrapyramidal side effects such as Parkinsonism and tardive dyskinesia?

• A. They block serotonin 5-HT2A receptors in the motor cortex, disrupting voluntary movement
• B. They block D2 receptors throughout the brain without selectivity, including in the nigrostriatal dopamine pathway that controls motor function
• C. They deplete dopamine synthesis globally, starving all dopaminergic pathways equally
• D. They cross the blood-brain barrier too slowly, accumulating in motor regions first

Answer: (B)

First-generation antipsychotics like haloperidol block D2 receptors nonselectively throughout the brain. The therapeutic effect comes from blocking D2 in the mesolimbic pathway (reducing aberrant salience), but the same blockade in the nigrostriatal pathway (which uses dopamine to coordinate smooth voluntary movement) produces Parkinsonism, akathisia, and with chronic use, tardive dyskinesia. Second-generation drugs add 5-HT2A blockade, which modulates dopamine release in a pathway-specific way, partially sparing nigrostriatal function and reducing (but not eliminating) motor side effects. Option A describes the wrong receptor and wrong region; option C is inaccurate about mechanism.

Question 3

Second-generation (atypical) antipsychotics have lower rates of extrapyramidal side effects than first-generation drugs, but carry significant metabolic risks including weight gain, elevated triglycerides, and increased diabetes risk.

• T. True
• F. False

Answer: True

True. The tradeoff is real and clinically important. Adding 5-HT2A blockade to D2 blockade modulates dopamine release in a pathway-selective way, reducing (though not eliminating) nigrostriatal effects and therefore lowering extrapyramidal side effects. But second-generation drugs — particularly clozapine and olanzapine — produce significant metabolic syndrome: weight gain, dyslipidemia, and glucose dysregulation that increases the risk of type 2 diabetes. This is not a theoretical risk; it is a leading cause of cardiovascular morbidity in patients with schizophrenia, who already have elevated cardiovascular risk. The choice between drug classes involves real tradeoffs, not a straightforward upgrade.

Question 4

Antipsychotic medications are equally effective at treating positive symptoms (hallucinations, delusions) and negative symptoms (flat affect, avolition) of schizophrenia.

• T. True
• F. False

Answer: False

False. This is a critical clinical misconception. Antipsychotics are highly effective at suppressing positive symptoms — the florid hallucinations and delusions driven by mesolimbic dopamine hyperactivity, which D2 blockade directly addresses. But they do little for negative symptoms, which are thought to reflect hypodopaminergic function in the mesocortical pathway (the prefrontal cortex, involved in motivation and executive function). Second-generation drugs modestly improve negative symptoms in some patients, but this effect is limited. The negative symptoms are often what prevent patients from returning to full functional life — working, socializing, living independently.

Question 5

Why is medication adherence particularly challenging with antipsychotics, and what clinical tool exists to address this problem?

Model answer: Adherence is difficult for several reasons: the side effect burden is subjectively experienced (weight gain is visible, akathisia is described as unbearable inner restlessness, sexual side effects are common), and many patients with psychosis lack insight into their own illness (anosognosia), making the cost-benefit calculation feel very different from their perspective than from their clinician's — they may not believe they are ill, so they see no reason to take medication that causes real side effects. Long-acting injectable (depot) antipsychotics address the adherence problem by delivering medication every 2–4 weeks, bypassing the need for daily oral dosing and removing the daily decision point.

The insight-adherence problem is central to managing chronic psychosis. Forced treatment is ethically fraught; voluntary adherence requires that patients agree their benefits outweigh the costs. Long-acting injectables shift the conversation: instead of a daily decision, there is a periodic clinic visit. They also allow clinicians to know definitively whether a patient is receiving medication — a crucial factor when evaluating whether symptoms represent inadequate response or nonadherence.